Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus TROSPIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus TROSPIUM CHLORIDE.
LUSEDRA vs TROSPIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Tropium chloride is a quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3), thereby reducing smooth muscle tone in the bladder, decreasing detrusor overactivity, and increasing bladder capacity.
5 mg orally once daily.
20 mg orally twice daily, extended-release 60 mg orally once daily in the morning.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life: 10-20 hours (mean 14 hours); clinical context: supports twice-daily dosing
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Renal: 65% (40% unchanged, 25% as metabolites); Fecal/Biliary: 35% (primarily via bile)
Category C
Category A/B
Anticholinergic
Anticholinergic